CD5CAR NK-92 cells (iCell)

N/A

Report date: 2022/09/05 17:48:28

Base Information

Drug NameCD5CAR NK-92 cells (iCell)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionT-cell surface glycoprotein CD5 inhibitors
TargetsT-cell surface glycoprotein CD5
Therapy Area/IndicationsLymphoma, T-CellLeukemia, T-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesiCell Gene Therapeutics LLC
China Registration ClassN/A

Develop Information

Active CompaniesiCell Gene Therapeutics LLC
Inactive CompaniesN/A
Active IndicationsLymphoma, T-CellLeukemia, T-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A